NotizieAssistito da IA

Xiogenix Collaboration Enhances Cellipont's Capabilities

Cellipont partners with Xiogenix to adopt Ares™ X20 system, boosting cell therapy manufacturing precision.

Di Priyanka Patil

Collaboratore marketing · Pharma Now

11 dic 2024Updated Jun 26, 2025 · 2 min di lettura

Condividi Aggiungi come fonte preferita

Xiogenix Collaboration Enhances Cellipont's Capabilities — https://www.constant-content.com/content-writing-service/2017/01/5-ways-you-can-collaborate-with-other-companies-and-grow-your-reach/

Giornalismo assistito da IA

Reviewed by Priyanka Patil, Collaboratore marketing · Pharma Now

Cellipont Bioservices, a leading CDMO in cell therapy, has partnered with Xiogenix to integrate the Ares™ X20 fill-and-finish system into its offerings. This advanced system automates formulation, ensures precise temperature control, and processes containers efficiently, optimizing manufacturing quality and scalability.

The partnership aims to enhance Cellipont's production capabilities, ensuring high standards in cell therapy development. Darren Head, CEO of Cellipont, and Rachel Bahr, CEO of Xiogenix, both emphasized the collaboration's potential to innovate biopharmaceutical manufacturing and accelerate the delivery of cutting-edge therapies to market.

ArgomentiNotizie

Written by

Priyanka Patil

Collaboratore marketing · Pharma Now

Reporting on the science, business and regulation shaping the pharmaceutical industry.